Research Topics
| Robert C MillerSummaryAffiliation: Mayo Clinic Country: USA Publications
| Collaborators
|
Detail Information
Publications
Controversies in clinical trials in proton radiotherapy: the present and the futureRobert C Miller
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Semin Radiat Oncol 23:127-33. 2013....- Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapyChristopher L Hallemeier
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Am J Clin Oncol 34:567-72. 2011..To evaluate preoperative CA 19-9 level as a prognostic factor in patients with resected adenocarcinoma of the pancreas... - Marital status and quality of life in patients with esophageal cancer or Barrett's esophagus: the mayo clinic esophageal adenocarcinoma and Barrett's esophagus registry studyRobert C Miller
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Dig Dis Sci 55:2860-8. 2010..Patients with esophageal carcinoma (EC) report deficits in quality of life (QOL), depending on the extent of malignant disease and the goals of treatment at the time of QOL measurement... 
Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4Robert C Miller
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 79:1460-6. 2011..A two-arm, double-blind, randomized trial was performed to evaluate the effect of 0.1% mometasone furoate (MMF) on acute skin-related toxicity in patients undergoing breast or chest wall radiotherapy...
Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experienceRobert C Miller
Department of Radiation Oncology, Mayo Clinic, Rochester, MN55905, USA
Int J Radiat Oncol Biol Phys 66:1178-86. 2006..The aim of this study was a retrospective assessment of neurotoxicity in patients with multiple sclerosis (MS) receiving external beam radiotherapy (EBRT) to the brain...- Intraoperative radiotherapy for treatment of locally advanced and recurrent esophageal and gastric adenocarcinomasR C Miller
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Dis Esophagus 19:487-95. 2006..For patients with isolated local recurrences, IORT may be effective salvage therapy. However, more effective systemic therapy is needed as a component of treatment... - Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposiumRobert C Miller
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Int J Radiat Oncol Biol Phys 75:364-8. 2009..To present an overview of Phase III trials in adjuvant therapy for pancreatic cancer and review outcomes at the Mayo Clinic after adjuvant radiochemotherapy (RT/CT) for resected pancreatic cancer... - Intraperitoneal treatment for peritoneal mucinous carcinomatosis of appendiceal origin after operative management: long-term follow-up of the Mayo Clinic experienceDavid A Schomas
Department of Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Ann Surg 249:588-95. 2009..To determine prognostic factors and the impact of intraperitoneal (IP) treatment after surgical resection of peritoneal mucinous carcinomatosis (PMC) of appendiceal origin... - Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic ExperienceDouglas G Gold
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Int J Radiat Oncol Biol Phys 75:150-5. 2009..To analyze the effect of adjuvant chemoradiotherapy on gallbladder carcinoma... - Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumorsBrandon M Barney
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Am J Clin Oncol 35:537-42. 2012..To present clinical outcomes, early toxicity, and dosimetric constraints for patients undergoing stereotactic body radiation therapy (SBRT) for abdominal or pelvic tumors... - The prognostic importance of pathologically involved celiac node metastases in node-positive patients with carcinoma of the distal esophagus or gastroesophageal junction: a surgical series from the Mayo ClinicDavid A Schomas
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Dis Esophagus 23:232-9. 2010..Therefore, treatment with curative intent should be considered for fit patients with celiac node disease... - Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4)Michelle A Neben-Wittich
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 81:397-402. 2011..However, prospectively planned secondary analyses of patient-reported outcomes (PROs), using the Skindex-16 and Skin Toxicity Assessment Tool (STAT), were positive. This study assesses the relationship between PA outcomes and PROs... - Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survivalJames M Donahue
Division of General Thoracic Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA
Ann Thorac Surg 87:392-8; discussion 398-9. 2009..Neoadjuvant chemoradiotherapy followed by esophagogastrectomy has become the standard of care for patients with locally advanced esophageal cancer. This report analyzes our experience with this treatment approach... - Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993)Pamela J Atherton
Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
Support Care Cancer 20:1729-35. 2012..The patient-reported Skindex-16 measures symptoms and perceptions of toxicity. This study was designed to compare information provided by these two measures... - Systemic lupus erythematosus, radiotherapy, and the risk of acute and chronic toxicity: the Mayo Clinic ExperienceMelva E Pinn
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 71:498-506. 2008..To determine the acute and chronic toxic effects of radiotherapy in patients with systemic lupus erythematosus (SLE)... - Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CAJames A Martenson
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 26:5248-53. 2008..To assess the effectiveness of depot octreotide for the prevention of diarrhea during pelvic radiation therapy... - Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005)Michele M Corsini
Department of Radiation Oncology the Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 26:3511-6. 2008..To determine prognostic factors and impact of adjuvant chemotherapy (CT) and radiotherapy (RT) on overall survival (OS) after resection of pancreatic adenocarcinoma... - Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreasMatthew J Iott
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Clin J Oncol Nurs 12:599-605. 2008.... - Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractionsMichael C Stauder
Department of Radiation Oncology, Mayo Clinic, Rochester, USA
Radiother Oncol 99:166-71. 2011..Identify the incidence of early pulmonary toxicity in a cohort of patients treated with lung stereotactic body radiation therapy (SBRT) on consecutive treatment days... - Stereotactic body radiation therapy in spinal metastasesKamran A Ahmed
Mayo Medical School, College of Medicine, Mayo Clinic, Rochester, MN, USA
Int J Radiat Oncol Biol Phys 82:e803-9. 2012..Based on reports of safety and efficacy, stereotactic body radiotherapy (SBRT) for treatment of malignant spinal tumors was initiated at our institution. We report prospective results of this population at Mayo Clinic... - Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experienceSumita Bhatia
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 66:514-9. 2006..The effect of adjuvant therapy on outcomes for patients with poor histologic grade or T3/T4 tumors without LN involvement could not be assessed... - Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative studyAmol K Narang
Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Radiat Oncol 6:126. 2011..We combined the experience of two institutions to better delineate which patients may benefit from adjuvant chemoradiation... - Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: a comparative dosimetric analysisO Kenneth Macdonald
Department of Radiation Oncology, Mayo Clinic, 200 1st Street S W, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 75:950-8. 2009..We analyzed the dosimetric differences between PT and SBRT in treating primary peripheral early-stage non-small-cell lung cancer... - Chronic toxicity risk after radiotherapy for patients with systemic sclerosis (systemic scleroderma) or systemic lupus erythematosus: association with connective tissue disorder severityDouglas G Gold
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Radiother Oncol 87:127-31. 2008..Building on our prior experience, we postulated that disease severity, as measured by the number of organ systems involved, may predict chronic radiation toxicity risk... - Combined modality therapy including intraoperative electron irradiation for locally recurrent colorectal cancerMichael G Haddock
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 79:143-50. 2011..To evaluate survival, relapse patterns, and prognostic factors in patients with colorectal cancer relapse treated with curative-intent therapy, including intraoperative electron radiation therapy (IOERT)... - Acute and late toxicities of radiotherapy for patients with discoid lupus erythematosus: a retrospective case-control studyAjaykumar B Patel
Department of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Radiat Oncol 7:22. 2012..The purpose of this study was to evaluate acute and late toxicities of radiotherapy for patients with discoid lupus erythematosus (DLE)... - Testicular cancer survivorship: research strategies and recommendationsLois B Travis
Department of Radiation Oncology, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
J Natl Cancer Inst 102:1114-30. 2010..Just as testicular cancer once served as the paradigm of a curable malignancy, comprehensive follow-up studies of testicular cancer survivors can pioneer new methodologies in survivorship research for all adult-onset cancer... - Incidence of brain metastasis in patients with esophageal carcinomaRon S Smith
Department of Radiation Oncology, Andreas Cancer Center Mayo Health System, Mankato, MN 56002, USA
World J Gastroenterol 17:2407-10. 2011..To determine the incidence of brain metastasis in a contemporary group of patients with carcinoma of the esophagus... - Cumulative morbidity and late mortality in long-term survivors of exocrine pancreas cancerNisha L Jacobs
Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
J Gastrointest Cancer 40:46-50. 2009..As a result, few studies have focused on these patients' cumulative, cancer-related morbidity and late mortality. This descriptive study was undertaken to explore such issues... - Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CAPamela J Atherton
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA
Support Care Cancer 21:1193-9. 2013..The Bowel Function Questionnaire (BFQ) has been used in clinical trials to assess symptoms during and after pelvic radiotherapy (RT). This study evaluated the importance of symptoms in the BFQ from a patient perspective... - The clinical case for proton beam therapyRobert L Foote
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Radiat Oncol 7:174. 2012..We review the clinical case for proton beam therapy. SUMMARY SENTENCE: Proton beam therapy is a technically advanced and promising form of radiation therapy... - Radiotherapy for malignancy in patients with scleroderma: The Mayo Clinic experienceDouglas G Gold
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 67:559-67. 2007..To determine the frequency of acute and chronic adverse effects in patients with scleroderma who receive radiotherapy for treatment of cancer... - Intraoperative electron-beam radiotherapy and ureteral obstructionRobert C Miller
Division of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 64:792-8. 2006..CONCLUSIONS: Risk of UO after IOERT increases with dose. However, UO risk for ureters not receiving IOERT was also high, which suggests an underlying risk of ureteral injury from other causes... - Intensity-modulated radiotherapy for squamous cell carcinoma of the anal canal: efficacy of a low daily dose to clinically negative regionsJason A Call
Department of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Radiat Oncol 6:134. 2011..We aimed to assess outcomes of patients with anal cancer who underwent intensity-modulated radiotherapy (IMRT) and received less than 1.80 Gy/day... - Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trialRobert C Miller
North Central Cancer Treatment Group, Coordinating Center, Rochester, MN, USA
Int J Radiat Oncol Biol Phys 54:409-13. 2002..This risk does not appear to persist during chemotherapy after completion of pelvic RT... - Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinomaBrandon M Barney
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA
Radiat Oncol 7:67. 2012..To report single-institutional clinical outcomes and toxicity with SBRT for cholangiocarcinoma... - A historical prospective cohort study of carotid artery stenosis after radiotherapy for head and neck malignanciesPaul D Brown
Division of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 63:1361-7. 2005..CONCLUSIONS: For long-term survivors after neck dissection and irradiation, especially those who are symptomatic, ultrasonographic carotid artery screening should be considered... - Informed consent in advanced laryngeal cancerRobert L Foote
Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Head Neck 29:230-5. 2007..This study was designed to evaluate the relationship between the informed consent process and the treatment received by patients with advanced laryngeal cancer... - Radiation-induced optic neuritis after pituitary adenoma radiosurgery in a patient with multiple sclerosis: case reportThomas B Daniels
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
J Neurooncol 93:263-7. 2009..To describe a rare case of optic neuritis onset after Gamma Knife stereotactic radiosurgery... - Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancerJann N Sarkaria
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Thorac Oncol 2:751-7. 2007..The safety and tolerability of sirolimus combined with thoracic radiation and cisplatin was evaluated in patients with lung cancer. In parallel, the effects of sirolimus were studied in a murine model of radiation pneumonitis... - Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlatesJohn M Schallenkamp
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 67:410-6. 2007..To define clinical and dosimetric parameters correlated with the risk of clinically relevant radiation pneumonitis (RP) after thoracic radiotherapy... - Phase III study of pentosanpolysulfate (PPS) in treatment of gastrointestinal tract sequelae of radiotherapyMiljenko V Pilepich
Department of Radiation Oncology, UCLA, Los Angeles, CA, USA
Am J Clin Oncol 29:132-7. 2006..To evaluate the effectiveness of pentosanpolysulfate (PPS) in the treatment of gastrointestinal tract sequelae of radiotherapy... - Radiotherapy for marginally resected, unresectable or recurrent giant cell tumor of the bone: a rare cancer network studySumita Bhatia
Mayo Clinic, Rochester, MN, USA
Rare Tumors 3:e48. 2011..This study reports a large published experience in the treatment of GCToB with radiotherapy. Radiotherapy can provide excellent local control for incompletely resected, unresectable or recurrent GCToB with acceptable morbidity... - Adjuvant chemoradiotherapy for resected pancreas cancerMatthew Iott
Matthew Iott, Michelle Neben Wittich, Robert C Miller, Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, United States
World J Gastrointest Surg 2:373-80. 2010..The debate will likely continue. Current practice should be based on the weight of evidence available at this time, which is in favor of adjuvant chemotherapy with chemoradiotherapy... - Curing patients with locally advanced esophageal cancer: an update on multimodality therapyK P McKian
Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Dis Esophagus 19:448-53. 2006..This review discusses recent studies in this field and outlines promising versus less promising therapeutic strategies... - Non-traumatic vertebral fractures in patients with locally advanced esophageal cancer: a previously unreported, unrecognized problemH McKean
Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Dis Esophagus 20:102-6. 2007..If confirmed, future studies should focus on identifying risk factors and optimal strategies for the prevention and treatment of vertebral fractures in patients with esophageal cancer... - Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus cancerA Gines
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
Dis Esophagus 21:241-50. 2008..With respect to the optimal treatment for each patient, agreement among physicians incrementally increases with endoscopic ultrasound results. Specialty training appears to influence therapeutic decision-making behavior... - Primary spinal epidural lymphoma: patients' profile, outcome, and prognostic factors: a multicenter Rare Cancer Network studyVirginie Monnard
Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Int J Radiat Oncol Biol Phys 65:817-23. 2006..After therapy, local control is excellent and systemic relapse occurs in less than half the cases. Combined modality treatment appears to be superior to RT alone... - Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer NetworkAurelius Omlin
Department of Radiation Oncology, University of Bern, Inselspital, Bern, Switzerland
Lancet Oncol 7:652-6. 2006..33 [95% CI 0.16-0.71], p=0.004; with boost, 0.15 [0.06-0.36], p<0.0001). INTERPRETATION: In the absence of randomised trials, boost radiotherapy should be considered in addition to surgery for breast-conserving treatment for DCIS... - Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma: a Rare Cancer Network studyEnis Ozyar
Hacettepe University, Oncology Institute, Ankara, Turkey
Radiother Oncol 81:39-46. 2006..This Rare Cancer Network (RCN) study was performed in pediatric nasopharyngeal carcinoma (PNPC) patients to evaluate the optimal dose of radiotherapy and to determine prognostic factors... - Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: a retrospective study from the Rare Cancer NetworkDamien C Weber
University Hospital of Geneva, Geneva, Switzerland
Int J Radiat Oncol Biol Phys 66:179-86. 2006..The aim of this study was to assess the outcome in patients with cerebellar glioblastoma (GBM) treated in 15 institutions of the Rare Cancer Network... - Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experienceJoseph K Salama
Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
J Clin Oncol 25:4581-6. 2007..To report a multicenter experience treating anal canal cancer patients with concurrent chemotherapy and intensity-modulated radiation therapy (IMRT)... - Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapyLoren K Mell
Department of Radiation and Cellular Oncology, University of Chicago and University of Illinois at Chicago, Chicago, IL 60637, USA
Int J Radiat Oncol Biol Phys 70:1431-7. 2008.... - Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN)Hadassah Goldberg
Division of Oncology, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion, Haifa, Israel
Gynecol Oncol 108:298-305. 2008..Uterine papillary serous carcinoma (UPSC) is a rare subtype of endometrial carcinoma, characterized by a poor outcome. We sought to better analyze the effect of surgery and adjuvant therapies on this disease... - Lung V20 measurements: In regard to Seppenwoolde et al. (Int J Radiat Oncol Biol Phys 2003;55:724-735), and Tsujino et al. (Int J Radiat Oncol Biol Phys 2003;56:1208-1209)Yolanda I Garces
Int J Radiat Oncol Biol Phys 58:1636; author reply 1636-7. 2004